Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
BURLINGTON, Mass., Feb. 07, 2017 -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2016 financial results on Tuesday, February 21, 2017, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.
Access to the live call is available by dialing 844-239-5284 (+1-512-961-6497 for international callers), passcode 66556990. The call can also be accessed live or via replay through a webcast at www.lemaitre.com/investor.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
LeMaitre and the LeMaitre Vascular logo are registered trademarks of LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. Steven Chehames Investor Relations +1-781-425-1659 [email protected] http://www.lemaitre.com
